Torrent Pharmaceuticals Ltd (TORNTPHARM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Torrent Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Change in Corporate Address of KFin (RTA) - w.e.f. 01-Dec-26
Others (Uncategorized) · 05 Nov 2026, 12:27 am
Torrent Pharmaceuticals Announces Relocation of RTA KFin Technologies Corporate Office Torrent Pharmaceuticals Limited announced that its Registrar and Share Transfer Agent, KFin Technologies Limited, will shift its Corporate Office to Rajapushpa West Avenue, Kokapet, Hyderabad, effective 1st Dec'26. The RTA's Registered Office remains unchanged. All future correspondence, notices, and documentation intended for the RTA's Corporate Office must be directed to the new location starting 1st Dec'26.
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter and half year ended 30th September, 2026
Transcript · 29 Oct 2026, 3:29 pm
Torrent Pharma Releases Q2-FY27 Earnings Conference Call Transcript Torrent Pharmaceuticals has made available the transcript of its conference call with analysts and investors regarding the financial results for the quarter and half year ended 30th Sep'26. In accordance with Regulation 30(6) of SEBI LODR Regulations, 2015, the complete transcript has been published on the company's official website for stakeholder review.
Recording Link of Analyst call - Q2 Results
Audio / Video · 24 Oct 2026, 1:14 am
Torrent Pharma Releases Q2 and H1 FY27 Analyst Call Audio Recording Torrent Pharmaceuticals Limited has made available the audio recording of its analyst and investor conference call regarding the financial results for the quarter and half-year ended 30th Sep'26. In compliance with Regulation 30(6) of SEBI LODR Regulations, 2015, the complete recording has been uploaded to the company's official website for stakeholder access.
Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 23 Oct 2026, 10:15 pm
Outcome of Board Meeting dated 23-Oct-26
Outcome · 23 Oct 2026, 10:03 pm
Results for quarter and half year ended 30-Sep-26
Financial Result · 23 Oct 2026, 10:00 pm
Torrent Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 4,979 (+50.8% YoY | +1.2% QoQ) ■ EBITDA: 1,666 (+53.8% YoY | +0.1% QoQ) ■ EBITDA Margin (%): 33.5 (+66 bps YoY | -35 bps QoQ) ■ PAT: 534 (-9.6% YoY | -5.7% QoQ) ■ EPS (INR): 14.1 (-19.5% YoY | -5.5% QoQ)
Change in Senior Management Personnel (SMP)
Change in Management · 16 Oct 2026, 11:32 pm
Torrent Pharma Announces Resignation of Executive Director Amal Kelshikar Torrent Pharmaceuticals Limited announced that Amal Kelshikar, Executive Director designated as Senior Management Personnel (SMP), has tendered his resignation effective from the close of business hours on 16th Oct'26. Kelshikar decided to transition following an extended tenure beyond superannuation and will support the company through a smooth transition and handover process.
Post Quarterly Financial Result Conference call with investors / analyst
Intimation · 23 Oct 2026, 5:30 pm
Torrent Pharmaceuticals Schedules Q2 and H1 Earnings Conference Call Torrent Pharmaceuticals Limited will host an earnings conference call for investors and analysts on 23rd Oct'26 at 05:30 PM IST. The management will discuss the company's financial performance for the quarter and half-year ended 30th Sep'26. Universal access dial-in numbers include +91 22 6280 1439 and +91 22 7115 8803, alongside international toll-free numbers and pre-registration access via Diamond Pass.
Intimation of Credit Rating
Others (Uncategorized) · 08 Oct 2026, 1:01 am
India Ratings Revises Torrent Pharma's Outlook to Positive; Affirms Ratings India Ratings and Research has affirmed Torrent Pharmaceuticals' credit rating at IND AA+ while revising the outlook to Positive from Stable for its existing banking facilities, issuer rating, and Non-Convertible Debentures (NCDs). Additionally, the agency affirmed and assigned an IND A1+ rating for the company's existing and proposed Commercial Paper programs, respectively.
Torrent Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to consider and approve the Half Yearly Audited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 23 Oct 2026, 5:30 am
Torrent Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to consider and approve the Half Yearly Audited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 23 Oct 2026, 5:30 am
the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-26.
Intimation · 23 Oct 2026, 5:30 am
To consider other business matters
Intimation · 23 Oct 2026, 5:30 am
Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve the Audited Financial ....
Intimation · 23 Oct 2026, 5:30 am
Torrent Pharma Schedules Board Meeting on 23rd Oct'26 for Q2 Financial Results Torrent Pharmaceuticals has scheduled a Board of Directors meeting on 23rd Oct'26 to consider and approve the standalone audited financial results and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26.
Disclosure pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations
Others (Uncategorized) · 28 Sept 2026, 5:30 pm
Torrent Pharma Increases Investment in Torrent Urja 27 to INR 11.88 Cr Torrent Pharmaceuticals executed an amendment agreement on 28th Sep'26 to raise its cash investment in Torrent Urja 27 Private Limited from INR 7.92 Cr to INR 11.88 Cr due to increased project capacity. The company will acquire a 26% stake (1,18,79,010 Class A equity shares at INR 10 face value) to secure captive hybrid renewable power (solar and wind) for its Gujarat operations. The related-party transaction is done at arm’s length and is expected to complete within 18 to 21 months.
Intimation of Schedule of Investor Meets
Intimation · 11 Sept 2026, 2:56 am
Torrent Pharmaceuticals Schedules Institutional Investor Meetings Across Sep'26 Torrent Pharmaceuticals has scheduled participation in multiple investor conferences under Regulation 30 of SEBI (LODR) Regulations, 2015. Company representatives will attend the Jefferies India Forum 2026 in Gurgaon on 17th Sep'26, followed by the Kotak Healthcare Forum 2026 on 18th Sep'26 and the JP Morgan India Conference on 21st Sep'26, both in Mumbai. The interactions across all three events will consist of group and one-on-one meetings, subject to schedule adjustments based on operational exigencies.
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation · 11 Aug 2026, 9:56 pm
Torrent Pharma to Participate in Emkay - Confluence 2026 Investor Meeting Torrent Pharmaceuticals has scheduled an investors' meet on 14-Aug-26 in Mumbai. Company representatives will participate in the "Emkay - Confluence 2026" event, which will include both group and one-on-one meetings with investors. This engagement is disclosed under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements. The schedule is subject to change based on exigencies.
ESG Rating
Others (Uncategorized) · 11 Aug 2026, 8:21 pm
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026
Transcript · 04 Aug 2026, 6:04 pm
Torrent Pharma Publishes Q1 FY27 Earnings Call Transcript Torrent Pharmaceuticals has released the transcript of its analyst and investor conference call held to discuss financial results for the quarter ended 30th Jun'26. The document, dated 04th Aug'26, provides detailed insights from management on the company's performance and outlook. It is now available on the company's website for investor review, in compliance with SEBI's listing regulations. The transcript is a key resource for understanding the drivers behind the Q1 FY27 results.
Intimation of Cessation of Director of the Company
Change in Management · 02 Aug 2026, 3:01 am
Torrent Pharma: Independent Director Ameera Shah's Term Concludes Torrent Pharmaceuticals announced that Ameera Shah (DIN: 00208095) has ceased to be an Independent Director of the company effective 01-Aug-26. The change in directorship is due to the completion of her term. This information was disclosed to the BSE and NSE as per SEBI's Listing Regulations.
Recording Link of Analyst call - Q1 Results
Audio / Video · 31 Jul 2026, 1:08 am
Torrent Pharma Publishes Q1 FY27 Analyst Call Recording Torrent Pharmaceuticals has released the audio recording of its analyst and investor conference call held to discuss financial results for the quarter ended 30th Jun'26. The recording, made available on 30th Jul'26, is accessible on the company's website. This follows the company's earlier communication on 17th Jul'26 and complies with SEBI's disclosure regulations. Investors can access the file to hear management's commentary on the quarterly performance and future outlook.
Change in Senior Management Personnel
Change in Management · 30 Jul 2026, 10:37 pm
Torrent Pharma Announces Senior Management Personnel Changes Torrent Pharmaceuticals announced that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni have ceased to be designated as Senior Management Personnel (SMPs) effective from 30 Jul'26. The company stated the reason for this change is a modification in its internal reporting structure. This update was filed under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements. No new appointments were announced in the filing.
Outcome of Board Meeting dated 30-Jul-26
Outcome · 30 Jul 2026, 10:29 pm
Torrent Pharma Q1FY27: Revenue Up 55% YoY, Driven By JB Pharma Acquisition Torrent Pharma reported strong Q1FY27 consolidated results for the quarter ending 30-Jun'26, driven by the amalgamation of JB Pharma. Revenue grew 55% YoY to ₹4,921 crores, while EBITDA rose 61% YoY to ₹1,664 crores, expanding margins to 33.8%. Net profit (PAT) stood at ₹566 crores, up 3% YoY. India business grew 19%, outperforming the market. US revenues surged 36% YoY to ₹418 crores. The company booked an exceptional charge of ₹21 crores, including a ₹19 crore inventory write-off from a fire incident.
Results for quarter ended 30-Jun-26
Financial Result · 30 Jul 2026, 10:21 pm
Torrent Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crore) ■ Revenue: 4,921 (+54.8% YoY | +17.3% QoQ) ■ EBITDA: 1,664 (+61.2% YoY | +22.7% QoQ) ■ EBITDA Margin (%): 33.8 (+134 bps YoY | +151 bps QoQ) ■ PAT: 566 (+3.3% YoY | +45.5% QoQ) ■ EPS (INR): 14.9 (-8.2% YoY | +29.2% QoQ)
Appointment of Shanti Ekambaram as an Independent Director of the Company
Change in Management · 28 Jul 2026, 3:34 pm
Torrent Pharma Appoints Banking Veteran Shanti Ekambaram to its Board Torrent Pharma has appointed Shanti Ekambaram as an Additional Independent Director for a three-year term, effective 30th Jul'26, subject to shareholder approval. Ms. Ekambaram, 63, is a distinguished banking leader with 39 years of experience, including a 35-year tenure at Kotak Mahindra Bank where she served as Deputy MD and Whole-time Director (2022-25). A Chartered Accountant, she currently serves on the boards of Kotak Securities, Havells India, and IIM Bangalore, bringing significant financial and governance expertise to the company.